Chiusura precedente | 7,29 |
Aperto | 7,12 |
Denaro | 6,36 x 200 |
Lettera | 7,77 x 200 |
Min-Max giorno | 7,06 - 7,89 |
Intervallo di 52 settimane | 3,82 - 36,60 |
Volume | |
Media Volume | 1.129.644 |
Capitalizzazione | 6,59M |
Beta (5 anni mensile) | 1,46 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -27,00 |
Prossima data utili | 10 mag 2024 - 14 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 33,75 |
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 2:00 PM
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the registered direct offe
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven track record of successfully developing oral biotherapeutics and locally acting immunomodulating t